Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response

Summary Objective Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring IL28B genotype CC should be treated with interferon (Peg-IFN) plus ribavirin (RBV). This study aimed to assess the rate of sustained virological response (SVR) in these subjects, according to...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2013-07, Vol.67 (1), p.59-64
Main Authors: Neukam, Karin, Barreiro, Pablo, Rivero-Juárez, Antonio, Caruz, Antonio, Mira, José A, Camacho, Angela, Macías, Juan, Rivero, Antonio, Soriano, Vicente, Pineda, Juan A
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - therapeutic use
Biological and medical sciences
Boceprevir
Cohort Studies
Drug Therapy, Combination - methods
Female
General aspects
Genotype
Hepatitis C
Hepatitis C virus
Hepatitis, Chronic - drug therapy
HIV
Human immunodeficiency virus
Humans
IL28B
Infectious Disease
Interferon alpha-2
Interferon-alpha - therapeutic use
Interferons
Interleukins - genetics
Male
Medical sciences
Middle Aged
Pegylated interferon
Pharmacology. Drug treatments
Polyethylene Glycols - therapeutic use
Prospective Studies
Rapid virological response
Recombinant Proteins - therapeutic use
Ribavirin
Ribavirin - therapeutic use
Spain
Telaprevir
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Objective Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring IL28B genotype CC should be treated with interferon (Peg-IFN) plus ribavirin (RBV). This study aimed to assess the rate of sustained virological response (SVR) in these subjects, according to whether they achieve rapid virological response (RVR) or not. Methods Prospective cohort study conducted at the Infectious Diseases Units of three Spanish hospitals. 220 treatment-naive, HCV genotype 1-infected patients, 160 of them HIV/HCV-coinfected, who initiated dual therapy with peg-IFN plus RBV were analyzed in an on-treatment approach. Results 29 (18%) HIV/HCV-coinfected and 14 (23%) HCV-monoinfected ( p  = 0.44) individuals developed RVR. In the overall population, 32 (39%) patients with IL28B genotype CC versus 11 (8%) bearing genotype non-CC achieved RVR ( p  
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2013.03.010